Osteoporosis in men;Osteoporoza u muškaraca

Lijecnicki Vjesnik

Volumn 126, Issue 3-4, 2004, Pages 76-79

  Kaštelan, Darko ^a   Giljeví, Zlato ^a   Aganović, Izet ^a   Koršic, Mirko ^a  

^a KBC Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; RISEDRONIC ACID; TESTOSTERONE; VITAMIN D;

ADULT; AGED; ALCOHOL ABUSE; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; HIP FRACTURE; HUMAN; HYPOGONADISM; MALE; OSTEOPOROSIS; REVIEW; SECONDARY OSTEOPOROSIS; PATHOLOGIC FRACTURE;

FRACTURES, SPONTANEOUS; HUMANS; MALE; OSTEOPOROSIS;

EID: 4644295956     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. Perspective: the diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
2. Looker AC, Orwoll ES, Johnston CC Jr i sur. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997;12:1761-8.
3. Melton LJ III, Atkinson EJ, O'Conor MK, O'Fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Miner Res 1998;13:1915-23.
4. Ross PD, Lombardi A, Freedholm D. The assessment of bone mass in men. U: Orwoll ES, ur. Osteoporosis in men. San Diego: Academic Press; 1999, str. 505-525.
5. Cheng S, Suominen H, Sakari-Rantala R, Laukkanen P, Avikainen V, Heikkinen E. Calcaneal bone mineral density predicts fracture occurrence: a five year follow up study in elderly people. J Bone Miner Res 1997;12:1075-82.
6. De Laet CEDH, van Hout BA, Burger H, Weel AEAM, Hofman A, Pols HAP. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998;13:1587-93.
7. Aaron JE, Makins NB. Sagreiy K. The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop 1987;215:260-71.
8. Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: a worldwide projection. Osteoporosis International 1992;2:285-9.
9. Oden A, Dawson A, Dere W, Johnell O, Johnson B, Kanis JA. Lifetime risk of hip fractures is underestimated. Osteoporosis Int 1998;8:599-603.
10. De Laet C, van Hout BA, Burger H, Hofman A, Pols HAP. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 1997;314:221-5.
11. Copper C, Atkinson EJ, O'Fallen WM, Melton III Lj. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992;7:221-7.
12. O'Neill TW, Felsenberg D, Varlow J i sur. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996;11:1010-8.
13. Poor G, Atkinson EJ, Lewallen DG, O'Fallon WM, Melton III LJ. Age related hip fractures in men: clinical spectrum and short-term outcome. Osteoporosis International 1995;5:419-26.
14. Eisman JA. Genetics of osteoporosis. Endocr Rev 1999;20:788-804.
15. Kannus P, Palvanen M, Kaprio J, Parkkari J, Koskenvuo M. Genetic factors and osteoporotic fractures in elderly people: prospective 25-year follow-up of a nationwide cohort of elderly Finnish twins. BMJ 1999; 319:1334-7.
16. Ferrari S, Manen D, Bonjour JP, Slosman D, Rizzoli R. Bone mineral mass and calcium and phopshate metabolism in young men: relationships with vitamin D receptor allelic polymorphisms. J Clin Endocrinol Metab 1999;84:2043-8.
17. Peris P, Alvarez L, Oriola J i sur. Collagen type 1 alpha 1 gene polymorphism in idiopathic osteoporosis in men. Rheumatology 2000;39:1222-5.
18. Rosen CJ, Kurland ES, Vereault D i sur. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998;83:2286-90.
19. Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, Piaseu N, Chailurkit L. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol 1998;49:803-9.
20. Zmuda MJ, Cauley JA, Kuller LH i sur. Androgen receptor CAG repeat length is associated with increased hip bone loss and vertebral fracture risk among older men. J Bone Miner Res 2000;15(Suppl 1):491.
21. Scane AC, Francis RM. Risk factors for osteoporosis in men. Clinical Endocrinology. 1993;38:15-6.
22. Finkelstein JS, Neer RM, Biller BMK, Crawford JD, Klibanski A. Osteopenia in men with a history of delayed puberty. N Engl J Med 1992; 326:600-4.
23. Colvard DS, Eriksen EF, Keeling PE i sur. Identification of androgenreceptors in normal human osteoblast-like cells. Proceedings of the National Academy of Sciences 1989;86:854-7.
24. Anderson FH, Francis RM, Selby PL, Copper C. Sex hormones and osteoporosis in men. Calcified Tissue International 1998;62:185-8.
25. Turner RT, Wakley GK, Hannon KS. Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res 1990;8:612-7.
26. Orwoll ES. Androgens. U: Bilezikian JP, Raisz LG, Rodan GR. Principles of bone biology. 1996, Academic Press, San Diego.
27. Bellido T, Jilka RJ, Boyce BF i sur. Regulation of interleukin-6, osteoclastogenesis and bone mass by androgens: the role of the androgen receptor. J Clin Invest 1989;95:2886-95.
28. Gori F, Haufbauer LC, Conover CA i sur. Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology 140:5579-86.
29. Francis RM, Peacock M, Aaron JE i sur. Osteoporosis in hypogonadal men: Role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption and low bone formation. Bone 1986;7:261-8.
30. Wei JT, Groww M, Jaffe CA i sur. Androgen deprivation therapy for prostate cancer results in significant bone loss of bone density. Urology 1999; 54:607-11.
31. Daniell HW. Osteoporosis after orchyectomy for prostate cancer. Journal of Urology 1997;157:439-44.
32. Slemenda C, Longcope C, Zhou L, Hut SL, Peacock M, Johnston CC. Sex steroids and bone mass in older men. Positive associations with serum estrogen and negative associations with androgens. Journal of Clinical Investigation 1997;100:1755-9.
33. Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters in the determination of osteoporosis in elderly man. Journal of Clinical Endocrinology and Metabolism 1999;84:3626-35.
34. Smith EP, Boyd J, Frank GR i sur. Estrogen resistance caused by a mutation in the estrogen-receptor gen in a man. New England Journal of Medicine 1994;331:1056-61.
35. Carani C, Qin K, Simoni M i sur. Effect of testosterone and estradiol in a man with aromatase deficiency. New England Journal of Medicine 1997;337:91-5.
36. Ljunghall S, Johansson AG, Burman P, Kampe O, Lindh E, Karlsson FA. Low plasma levels of insulin-like growth factor I (IGF-1) in male patients with idiopathic osteoporosis. Journal of Internal Medicine 1992; 232:59-64.
37. Reed BY, Zerwekh JE, Sakhaee K, Breslau NA, Gottschalk F, Pak CYC. Serum IGF-1 is low and correlated with osteoblastic surface in idiopathic osteoporosis. Journal of Bone and Mineral Research 1995;10:1218-24.
38. Kelepouris N, Harper KD, Cannon F i sur. Severe osteoporosis in men. Annals of Internal Medicine 1995;123:452-60.
39. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporosis Int 2000;11:192-202.
40. Wüster C, Hadji P. Use of Quantitative Ultrasound Densitometry (QUS) in Male Osteoporosis. Calcif Tissue Int 2001;69:225-8.
41. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386-90.
42. Anderson FH, Francis RM, Peaston RT, Watell HJ. Androgen supplementation in eugonadal men with osteoporosis-effects of six months' treatment on markers of bone formation and resorption. J Bone Miner res 1997;12:472-8.
43. Orwoll E, Ettinger M, Weiss S i sur. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.
44. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001;86:5252-5.
45. Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001;69:242-7.
46. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Therapy of idiopathic osteoporosis in men with parathyroid hormone: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85:3069-76.
47. Neer RM, Arnaud C, Zanchetta JR i sur. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Eng J Med 2001;344:1434-41.